Compare Essex Property Trust, Inc. (ESS) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs TransMedics Group Inc — how do they compare? Essex Property Trust, Inc. trades at $286.72 (market cap $18.08B), while TransMedics Group Inc trades at $87.67 (market cap $3.02B). The key difference: Essex Property Trust, Inc. is far larger — about 6× TransMedics Group Inc's market cap, and Essex Property Trust, Inc. pays a 3.68% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| ESS | TMDX | |
|---|---|---|
Market Cap | $18.08B | $3.02B |
Sector | Real Estate | Technology |
52-Week High | $298.33 | $150.42 |
52-Week Low | $239.61 | $61.99 |
Enterprise Value | $24.67B | $3.41B |
Dividend Yield | 3.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $281.27, down 0.69% on the day, with a bearish technical signal. The company reported a Q2 2026 EPS miss ($0.97 vs. $1.46 expected) but raised full-year FFO guidance. Revenue grew to $1.89B in 2025, with a strong net income margin of 35.48%, though profitability is projected to moderate in 2026. The stock is supported by a $2.59 dividend and a consensus price target of $305.86, implying potential upside.
The outlook is mixed: raised guidance and institutional buying signal confidence, but technical weakness and a high debt load pose risks. The stock offers income and growth potential if operational execution improves, yet faces headwinds from regional market softness and interest rate sensitivity.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
